NEW YORK--(BUSINESS WIRE)--Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Turbine, a predictive simulation company that is building a platform for interpreting human biology. Accenture’s investment will help Turbine further extend its capabilities to global biopharma companies that can benefit from Turbine’s ability to uncover hidden biological insights, with the potential to guide and accelerate key drug development workstreams..

纽约--（商业新闻短讯）--埃森哲（纽约证券交易所：ACN）通过埃森哲风险投资公司（Accenture Ventures）对Turbine进行了战略投资，Turbine是一家预测模拟公司，正在构建一个解释人类生物学的平台。埃森哲的投资将帮助涡轮机进一步将其能力扩展到全球生物制药公司，这些公司可以从涡轮机揭示隐藏的生物学见解的能力中受益，并有可能指导和加速关键的药物开发工作流程。

Turbine’s core technology, the Simulated Cell™ platform, utilizes machine learning to understand how human cells make decisions. The platform intricately models molecular interactions within and around cells, enabling virtual experiments in volumes that are nearly impossible to achieve in the physical world and revealing mechanisms that drive diseases and response to therapies..

涡轮机的核心技术是Simulated Cell™平台，它利用机器学习来了解人类细胞如何做出决策。该平台对细胞内和细胞周围的分子相互作用进行了复杂的建模，从而实现了在物理世界中几乎不可能实现的虚拟实验，并揭示了驱动疾病和对治疗反应的机制。

“Advanced technology and digital capabilities are clearly becoming substantial differentiators in the biopharma industry, and the future of drug discovery will be powered by AI,” said Tom Lounibos, global lead of Accenture Ventures. “Turbine’s AI-based platform has clearly demonstrated the ability to unlock high-quality biological insights for our clients across the biopharma industry.”.

埃森哲风险投资公司（Accenture Ventures）全球负责人汤姆·鲁尼波斯（TomLounibos）表示：“先进的技术和数字能力显然正在成为生物制药行业的重要区别，药物发现的未来将由人工智能推动。”。“Turbine基于人工智能的平台清楚地证明了为我们的生物制药行业客户提供高质量生物学见解的能力。”

Turbine’s platform is being validated with leading pharma companies to uncover promising drug targets, select patient populations most likely to benefit from therapy, and identify combination therapy regimens that can increase therapeutic benefit in certain patients. This allows Turbine to reveal treatments otherwise hidden from view, as well as potential drugs that work in the lab but would likely fail in clinical trials..

Turbine的平台正在与领先的制药公司进行验证，以发现有希望的药物靶标，选择最有可能从治疗中受益的患者人群，并确定可以增加某些患者治疗益处的联合治疗方案。这使得涡轮机能够揭示隐藏在视线之外的治疗方法，以及在实验室中起作用但可能在临床试验中失败的潜在药物。

Petra Jantzer, Ph.D., a senior managing director and global lead of the Accenture Life Sciences business, said, “Turbine's Simulated Cell™ platform has emerged as a valuable tool for global biopharma companies to gain insights into the intricacies of biological systems, which can lead to the development of targeted treatments.

埃森哲生命科学公司高级董事总经理兼全球负责人佩特拉·詹泽尔博士说：“涡轮机的模拟细胞™平台已经成为全球生物制药公司深入了解生物系统复杂性的宝贵工具，这可以导致靶向治疗的发展。

Our investment reflects our commitment to supporting technology and digital capabilities that drive innovation in AI-based drug discovery, all with the goal of providing more effective treatments and enhancing patient care.”.

我们的投资反映了我们对支持技术和数字能力的承诺，这些技术和数字能力推动了基于人工智能的药物发现的创新，所有这些都是为了提供更有效的治疗和加强患者护理。”

“Since most unsolved complex diseases are heterogenous, progress in utilizing AI for drug discovery is hindered by ethical and technological limitations in sourcing deep and diverse ground truth data. To bridge this gap, we need a toolkit that can learn fundamental rules of biology on in vitro experiments and apply to patients that it has never seen before.

“由于大多数未解决的复杂疾病都是异质性的，因此利用人工智能进行药物发现的进展受到伦理和技术限制，无法获得深入而多样的基本事实数据。为了弥合这一差距，我们需要一个工具包，可以学习体外实验生物学的基本规则，并适用于以前从未见过的患者。

Turbine's Simulated Cells can be engineered at scale to represent the heterogeneity of complex human disease better than currently available wet lab experimental models, which are inherently biased towards representing certain disease types and hardly scalable,” said Szabolcs Nagy, co-founder and CEO of Turbine.

Turbine联合创始人兼首席执行官Szabolcs Nagy说：“与目前可用的湿实验室实验模型相比，Turbine的模拟细胞可以大规模工程化，以更好地代表复杂人类疾病的异质性，而湿实验室实验模型本质上偏向于代表某些疾病类型，难以扩展。”

“By tapping into Accenture’s expertise, we hope to expand our market reach and augment our simulation platform in order to benefit the whole biopharma industry by ensuring that the next experiment is always the correct one.”.

“通过利用埃森哲的专业知识，我们希望扩大我们的市场范围，扩大我们的模拟平台，以确保下一个实验总是正确的，从而使整个生物制药行业受益。”

Turbine is the latest company to join Accenture Ventures’ Project Spotlight, an engagement and investment program focused on working with companies that create or apply disruptive enterprise technologies. Project Spotlight offers extensive access to Accenture’s domain expertise and its enterprise clients, helping startups harness creativity and deliver on the promise of their technology.

Turbine是最新加入埃森哲风险投资公司（Accenture Ventures）项目聚光灯（Project Spotlight）的公司，该项目是一项专注于与创造或应用颠覆性企业技术的公司合作的参与和投资计划。Project Spotlight提供了对埃森哲领域专业知识及其企业客户的广泛访问，帮助初创公司利用创造力并实现其技术的承诺。

Additional digital simulation companies in Project Spotlight include QuantHealth, Virtonomy and Ocean Genomics..

项目聚光灯下的其他数字模拟公司包括QuantHealth、Virtonomy和Ocean Genomics。

About Accenture

关于埃森哲

Accenture is a leading global professional services company that helps the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 742,000 people serving clients in more than 120 countries.

埃森哲是一家领先的全球专业服务公司，帮助世界领先的企业、政府和其他组织构建数字核心，优化运营，加速收入增长，增强公民服务，以速度和规模创造有形价值。我们是一家以人才和创新为主导的公司，拥有约742000名员工，为120多个国家的客户提供服务。

Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability.

技术是当今变革的核心，我们是帮助推动变革的世界领导者之一，拥有强大的生态系统关系。我们将我们在云、数据和人工智能领域的技术优势和领导地位与无与伦比的行业经验、功能专业知识和全球交付能力相结合。

We are uniquely able to deliver tangible outcomes because of our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song. These capabilities, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships.

由于我们在战略与咨询、技术、运营、X行业和Song领域提供了广泛的服务、解决方案和资产，因此我们能够提供切实的成果。这些能力，加上我们共享成功的文化和创造360°价值的承诺，使我们能够帮助客户重塑和建立值得信赖的持久关系。

We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at www.accenture.com..

我们通过为客户、彼此、股东、合作伙伴和社区创造的360°价值来衡量我们的成功。请访问www.accenture.com。

About Turbine

关于涡轮机

Countless resources and time get expended globally to research and advance novel therapies that end in clinical failure and no patient benefit. Imagine a world where it is possible to predict any potential drug’s effect on translatable biological models – including those that may not even be available for lab-based testing – while accurately representing patient biology.

全球花费了无数的资源和时间来研究和推进新的治疗方法，最终导致临床失败而对患者没有益处。想象一个世界，在这个世界上，可以预测任何潜在药物对可翻译生物模型的影响，包括那些甚至可能无法用于实验室测试的生物模型，同时准确地代表患者生物学。

Turbine is revolutionizing the status quo by working to ensure that we always run the right wet lab experiments..

涡轮机正在通过努力确保我们始终运行正确的湿实验室实验来彻底改变现状。

With machine learning that understands the logic by which human cells make decisions, Turbine has built the world’s first predictive simulation of patient biology. The Simulated Cell™ platform models the protein signaling that decides cell fate and facilitates in silico experiments at scales that are impossible in the physical world, to empower the biopharma industry by guiding experiments that identify and confirm disease driving mechanisms..

通过理解人类细胞做出决策的逻辑的机器学习，Turbine建立了世界上第一个患者生物学预测模拟。Simulated Cell™平台模拟决定细胞命运的蛋白质信号传导，并以物理世界中不可能的规模促进计算机实验，通过指导识别和确认疾病驱动机制的实验来增强生物制药行业的能力。

Turbine’s platform is being validated with leading pharma companies such as AstraZeneca, Ono Pharmaceutical, Cancer Research Horizons, and Bayer. In addition, Turbine has received funding from industry leaders such as MSD (Merck & Co, Inc. Rahway NJ, USA) Global Health Innovation Fund, Accel, and MassMutual Ventures, among others..

涡轮机的平台正在与领先的制药公司进行验证，如阿斯利康、小野制药、癌症研究地平线和拜耳。此外，涡轮机还获得了行业领导者的资助，例如MSD（Merck＆Co，Inc.Rahway NJ，USA）、全球健康创新基金、Accel和MassMutual Ventures等。

For more information, visit www.turbine.ai or follow Turbine on LinkedIn.

有关更多信息，请访问www.turbine.ai或在LinkedIn上关注turbine。

Copyright © 2024 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.

版权所有©2024埃森哲。保留所有权利。埃森哲及其徽标是埃森哲的注册商标。